- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04590326
Studie av REGN5668 administrert i kombinasjon med Cemiplimab eller REGN4018 hos voksne kvinner med tilbakevendende eggstokkreft
Fase 1/2-studie av REGN5668 (MUC16xCD28, en Costimulatory Bispecific) administrert i kombinasjon med Cemiplimab eller REGN4018 (MUC16xCD3)
This study is researching an investigational drug called REGN5668 :
- alone or,
- combined with cemiplimab (also known as REGN2810) or,
- combined with both cemiplimab and fianlimab (also known as REGN3767), or
- combined with ubamatamab (also known as REGN4018), with or without sarilumab.
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
- To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Studiesteder
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekruttering
- Universitair Ziekenhuis Leuven
-
-
-
-
-
São Paulo, Brasil, 01509-010
- Rekruttering
- AC Camargo Cancer Center, Fundacao Antonio Prudente
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90619-900
- Rekruttering
- Centro de Pesquisa em Oncologia PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Rekruttering
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Sorocaba, São Paulo, Brasil, 18065-100
- Rekruttering
- Unimed Sorocaba
-
-
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Forente stater, 92618
- Rekruttering
- The City of Hope Orange County Lennar Foundation Cancer Center
-
Orange, California, Forente stater, 92868
- Rekruttering
- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Fullført
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana Farber Cancer Institute Brookline Avenue
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Perelman School of Medicine at the University of Pennsylvania
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Seattle Cancer Care Alliance at South Lake Union - G3630
-
-
-
-
-
Villejuif, Frankrike, 94805
- Rekruttering
- Institut Gustave Roussy
-
-
Auvergne-Rhône
-
Pierre-Bénite, Auvergne-Rhône, Frankrike, 69310
- Rekruttering
- Hopital Lyon Sud
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Frankrike, 21000
- Rekruttering
- Centre Georges Francois Leclerc
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrike, 33076
- Rekruttering
- Institut Bergonie
-
-
Normandy
-
Caen, Normandy, Frankrike, 14076
- Rekruttering
- Centre Francois Baclesse (CFB)
-
-
-
-
-
Girona, Spania, 17007
- Rekruttering
- Institut Catala dOncologia Girona
-
Madrid, Spania, 28040
- Rekruttering
- Hospital Universitario Fundacion Jimenez
-
Madrid, Spania, 28040
- Rekruttering
- Ciudad Universitaria
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spania, 15706
- Rekruttering
- Hospital Clinico Universitario Santiago de Compostela
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a Mucin 16 (MUC16)-targeted therapy
- Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Module 1
REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab |
Administer per the protocol
Andre navn:
Administer per the protocol
Andre navn:
Administer per the protocol |
|
Eksperimentell: Module 2
REGN5668 and ubamatamab |
Administer per the protocol
Andre navn:
Administer per the protocol
Andre navn:
Administer per the protocol
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
Tidsramme: 42 days
|
Dose escalation phase, Module 1 |
42 days
|
|
Incidence of DLTs
Tidsramme: 21 days post combination administration
|
Dose escalation phase, Module 2 |
21 days post combination administration
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of Serious Adverse Events (SAEs)
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of deaths
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose escalation phase |
Through study completion, up to 5 years
|
|
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tidsramme: Through study completion, up to 5 years
|
Primary: Dose expansion phase |
Through study completion, up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
ORR based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years
|
Dose escalation phase |
Through study completion, up to 5 years
|
|
Best Overall Response (BOR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Duration Of Response (DOR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Disease Control Rate (DCR) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Progression-Free Survival (PFS) based on RECIST 1.1
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against REGN5668
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against ubamatamab
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against cemiplimab
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against fianlimab
Tidsramme: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Patologiske prosesser
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdomsattributter
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Neoplasmer i endokrine kjertel
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Uterine neoplasmer
- Eggledersykdommer
- Patologiske tilstander, tegn og symptomer
- Tilbakefall
- Neoplasmer i eggstokkene
- Endometriale neoplasmer
- Egglederneoplasmer
- Cemiplimab
- Sarilumab
Andre studie-ID-numre
- R5668-ONC-1938
- 2022-501904-83-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Tilgangskriterier for IPD-deling
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .